BTX News and Press, Brooklyn ImmunoTherapeutics Inc. From 05/10/19

BioTime, Inc. (BTX) Q1 2019 Earnings Conference Call May 09, 2019 4:30 PM ET Company Participants Ioana Hone - Director of Investor Relations Brian Culley - Chief Executive Officer Brandi Roberts - Chief Financial Officer Ed Wirth - Chief Medical Officer Gary Hogge - Senior V...

BioTime (NYSEMKT: BTX ): Q1 EPS of $0.30 may not be comparable to consensus of -$0.07. Revenue of $0.9M (+28.6% Y/Y) beats by $0.26M . Press Release More news on: BioTime, Inc., Earnings news and commentary, Healthcare stocks news, ,

Positive OpRegen ® Data Presented at Association for Research in Vision and Ophthalmology Annual Meeting Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury Entered Into Exclusive Collaboration with Orbit Biome...

BioTime stock is currently selling for $1.18 USD on the NYSE American exchange. At the time of writing, shares are down nearly 5%. Despite a rough few trading days, BTX stock has a consensus rating of “Buy” from six analysts. So let’s check this out. BioTime Stock ...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance for a patent from the United States Patent and Trademark Office (USPTO) for United States Patent Applicat...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial and operating results on Thursday, May 9 th , 2019, following the close of the U.S. financial markets....

Treatment with OpRegen ® Continues to be Well Tolerated with Signs of Structural Improvement in the Retina Observed in Some Patients BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that ...

The following slide deck was published by BioTime, Inc. in conjunction with this Read more ...

Noteworthy events during the week of April 28 - May 4 for healthcare investors. More news on: Catalyst Biosciences, Inc., Aldeyra Therapeutics, Inc., BioTime, Inc., Healthcare stocks news, , Read more ...

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that Edward D. Wirth, III, M.D., Ph.D., Chief Medical Officer of BioTime, will present at the 26 th Annual American Society for Neural Therapy and Repair...